FFA
RLMD icon

Farther Finance Advisors’s Relmada Therapeutics RLMD Stock Holding History

Farther Finance Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-684
Closed -$4.86K – 6090
2026
Q1 		$4.86K Hold
684
– – ﹤0.01% 4510
2025
Q4 		$3.3K Sell
684
-154
-18% -$516 ﹤0.01% 4495
2025
Q3 		$1.68K Buy
+838
New +$804 ﹤0.01% 4197

Other funds holding RLMD

PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
AW
Apricus Wealth Beaufort, South Carolina $210M AUM 30.06% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
ACA
American Capital Advisory Ketchum, Idaho $275M AUM 22.21% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Farther Finance Advisors's RLMD Position: Q2 2026 in Review

Farther Finance Advisors sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 684 shares — an estimated $4.86K sold.

Farther Finance Advisors first reported a position in RLMD in Q3 2025 and held it in 3 quarters. The position peaked at $4.86K in Q1 2026. 9 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Farther Finance Advisors reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Farther Finance Advisors sold 684 Relmada Therapeutics shares in Q2 2026, an estimated $4.86K.
  • Farther Finance Advisors first reported a position in Relmada Therapeutics in Q3 2025 and held it in 3 quarters.
  • Farther Finance Advisors's Relmada Therapeutics position peaked at $4.86K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.